Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Chemotherapy for germ cell tumors.

R J Motzer, G J Bosl

The Urologic Clinics of North America

|May 1, 1987

Summary

This summary is machine-generated.

Advanced germ cell tumors have high cure rates with cisplatin chemotherapy and surgery. Risk stratification using tumor markers and disease extent guides treatment for good-risk patients and highlights the need for novel therapies for poor-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER study.

ESMO open·2025

Same author

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Area of Science:

Oncology
Medical Oncology

Background:

Advanced germ cell tumors (GCTs) are increasingly curable with modern treatment regimens.
Cisplatin-based chemotherapy and surgery have significantly improved patient outcomes.
Serum tumor markers are crucial for diagnosis, prognosis, and monitoring treatment response in GCTs.

Purpose of the Study:

To review current treatment strategies for advanced germ cell tumors.
To discuss the role of risk stratification in tailoring therapy.
To identify future directions for improving cure rates, particularly in poor-risk patients.

Main Methods:

Review of existing literature on germ cell tumor treatment.
Analysis of prognostic factors including serum tumor markers, disease extent, histology, and primary site.

Related Experiment Videos

Discussion of treatment approaches for different risk groups.

Main Results:

A cure rate of 70-80% is achievable for advanced GCTs with current standard therapies.
Risk stratification effectively divides patients into 'good-risk' and 'poor-risk' categories.
Ongoing research focuses on optimizing treatment for good-risk patients to reduce toxicity and developing innovative therapies for poor-risk patients.

Conclusions:

Treatment advancements have led to high cure rates in advanced GCTs.
Personalized treatment strategies based on risk stratification are essential.
Further progress requires rigorous clinical trials and the development of novel therapeutic agents.